2022 Society for Investigative Dermatology (SID) Annual Meeting
May 21, 2022
Several faculty, trainees and researchers representing UW Dermatology presented their research at the SID Annual Meeting in Portland, Oregon from May 18-21, 2022.
Each year, the Society for Investigative Dermatology (SID)’s Annual Meeting invites a diverse group of researchers and clinicians, as well as hundreds of clinical trainees including residents, to exchange information on the latest advances in dermatology. The opportunity to interact with scientists who possess complementary knowledge, and present cutting-edge therapies has produced countless productive collaborations. In addition to the direct scientific goals, elements of the meeting are designed for the training and career development of young investigators.
2022 SID Presentations
Thursday, May 19, 2022
Abstract #825: Assessment of a circulating tumor DNA test for detecting recurrence of Merkel cell carcinoma
- Concurrent Mini-Symposium 5, Translational Studies
- T. Akaike, L. E. Gunnell, C. Doolittle-Amieva, K. Lachance, E. Hall, P. Nghiem
- Location: C123-C124
LB1044 Inhibitors of CDK4/6 and HIF2a induce immunogenic cell death in merkel cell carcinoma cells
- Concurrent Mini-Symposium 6, Late-Breaking Abstracts
- J. H. Lee, J. Lee, T. Pulliam, A. Berndt, C. Church, K. Lachance, S. Y. Park, P. Nghiem
- Location: Oregon Ballroom 201-202
Abstract #201: What is the risk of Merkel cell carcinomarecurrence beyond pathologically clear margins? An analysis of 926 cases
- Concurrent Mini-Symposium 1, Clinical Research – Epidemiology and Observational Research
- A. Fu, N. Singh, K. Lachance, D. Hippe, P. Nghiem, S. Y. Park
- Location: Oregon Ballroom 203
Friday, May 20, 2022
Abstract #541: Characterization of myeloid cell subsets in the tumor microenvironment of merkel cell carcinoma
- Concurrent Mini-Symposium 9, Innate Immunity, Microbiology, and Microbiome
- S. Tabachnick-Cherny, T. Pulliam, P. Nghiem
- Location: A105-A106
Abstract #826: Recurrence risk in seropositive merkel cell carcinoma: A web-based calculator to interpret merkel cell polyomavirus antibody test results
- E-Poster Session 2 – Translational Studies
- L. E. Gunnell, K. Lachance, D. Hippe, M. Bierma, K. Cahill, T. Akaike, P. Nghiem
- Location: Terminal #5-Room B112
Saturday, May 21, 2022
Abstract #292: Is it safe to discontinue immunotherapy after a response in merkel cell carcinoma?
- Concurrent Mini-Symposium 15, Clinical Research – Interventional Research
- L. Tachiki, L. Zawacki, Y. Moshiri, N. Alexander, T. Akaike, C. Doolittle-Amieva, T. Pulliam, S. Bhatia, P. Nghiem
- Location: A105-A106
2022 Abstracts
Abstract #179: Merkel cell carcinoma recurrence risk is lower in patients with autoimmune disease than in those with other types of immune suppression
- Clinical Research-Epidemiology and Observational Research
- S. Y. Park, D. Hippe, L. Zawacki, M. Bierma, S. Bhatia, P. Nghiem, N. Singh
Abstract #247 : Type of immunosuppression matters: Efficacy of immunotherapy in immunosuppressed Merkel cell carcinoma patients
- Clinical Research-Epidemiology and Observational Research
- E. Gong, L. Zawacki, A. Remington, M. Bierma, K. Lachance, T. Akaike, P. Nghiem
Abstract #848: Inhibition of ATR augments immunogenicity in merkel cell carcinoma: A promising approach to address resistance to anti-PD-1 immunotherapy
- Translational Studies
- R. Bhakuni, P. Goff, J. H. Lee, T. Pulliam, S. Tabachnick-Cherny, C. D. Morningstar, P. Nghiem
LB879: Friend or foe? Identification of MCPyV-specific B cells in Merkel cell carcinomas suggests a functional role in tumor immunity
- Adaptive and Auto-Immunity
- H. J. Rodriguez Chevez, T. Pulliam, A. Remington, P. Nghiem
LB1029: Correlation of merkel virus-specific CD8 T cells with response to immunotherapy in merkel cell carcinoma
- Translational Studies
- T. Pulliam, S. Jani, L. Jing, R. Kulikauskas, C. Church, D. Koelle, P. Nghiem